From: NAT10 as a potential prognostic biomarker and therapeutic target for HNSCC
Clinical-pathological parameters | Patients (n = 267) | MST (days) | HR (95% CI) | P value |
---|---|---|---|---|
NAT10 IHC | 0.012 | |||
 Low | 83 | 1872 | Reference |  |
 High | 156 | 1378 | 1.564 (1.105–2.213) |  |
 Negative | 28 | 1419 |  |  |
Age | 2.94E−05 | |||
 < 65 | 206 | 1738 | Reference |  |
 ≥ 65 | 61 | 510 | 2.399 (1.591–3.616) |  |
Stage | 0.068 | |||
 I&II | 172 | 1685 | Reference |  |
 III&IV | 95 | 1177 | 1.435 (0.974–2.114) |  |
HPV | 0.125 | |||
 Positive | 22 | 1664 | Reference |  |
 Negative | 245 | 1569 | 2.475 (0.776–7.874) |  |
Type | 0.005 | |||
 Primary | 219 | 1625 | Reference |  |
 Recurrent | 48 | 511 | 1.898 (1.211–2.974) |  |